APR 12, 2017 9:00 AM PDT

Keynote Presentation - Assessing Risk in Cervical Cancer Screening Management: The Role of HPV Genotyping

Sponsored by: Roche Diagnostics
Speaker

Abstract

Screening for cervical cancer represents one of the greatest successes achieved in disease prevention. Cytology has been central to cervical cancer screening programs for over 50 years and has contributed to the 70% decline in rates of cervical cancer in the developed world.3 By the 1990’s, HPV was recognized as a single, necessary cause of cancer of the cervix that was detected in 99.7% of cases of cervical cancer.4 Therefore, tests that detect infection with these high-risk HPV genotypes are now being used increasingly in cervical cancer screening programs.  The 2007 Consensus Guidelines for the Management of Women with Abnormal Cervical Cancer Screening Tests6 recognized the utility of using a combination of cervical cytology, tests for HPV, and genotype-specific HPV testing for women undergoing screening for cervical cancer. These guidelines were subsequently revised and now recommend the combination of cytology and HR HPV testing (cotesting) as the preferred method of screening in women ≥30 years, with HPV 16/18 genotype–specific testing an added option to triage women with negative cytology to colposcopy.7 Most recently, the FDA approved the use of the cobas HPV Test as the first-line primary screen and interim guidance for this screening strategy has been issued and supported by 3 professional societies.

 

The numerous guideline changes have presented challenges to both laboratories and clinicians. For laboratories, decisions needed to be made regarding which HPV assay to run and how to re-organize resources and workflow to accommodate changing guidelines. For clinicians, choosing the optimal screening strategy and then understanding how to manage the results has become a difficult task.

 

Today we will try to simplify approaches to cervical cancer screening and management by reviewing the role of HPV genotyping in risk management. Cytology and HPV genotyping results can be used to quantify risks so that we can identify women at the highest risk of having or developing cervical disease and conversely, to identify women at the lowest risk. By utilizing this risk assessment approach, laboratorians and clinicians will better be able to choose the most efficient screening methodology and also more easily manage results that are often confounding and confusing.


Show Resources
You May Also Like
MAY 11, 2021 10:00 AM PDT
C.E. CREDITS
MAY 11, 2021 10:00 AM PDT
Date: May 11, 2021 Time: 10:00zm PDT Your samples are some of the most valuable assets in the laboratory. After spending countless hours on extraction and preparation, your conclusions could...
OCT 20, 2021 10:00 AM PDT
C.E. CREDITS
OCT 20, 2021 10:00 AM PDT
Date: October 20, 2021 Time:10:00am (PDT), 1:00pm (EDT) As the prevalence of Diabetes continues to rise in many areas across the globe, healthcare providers continue to look for methods that...
DEC 09, 2021 11:00 AM PST
C.E. CREDITS
DEC 09, 2021 11:00 AM PST
Date: December 09, 2021 Time: 11:00am (PDT), 2:00pm (EDT) The burden of antimicrobial resistance (AMR) has been acknowledged worldwide by leading health institutes. Besides the need for new...
NOV 17, 2021 8:00 AM PST
C.E. CREDITS
NOV 17, 2021 8:00 AM PST
Date: November 17, 2021 Time: 8:00am (PDT), 11:00am (EDT) From waste disposal to promising biomarkers and therapeutic agents, exosomes and other extracellular vesicles are valuable in resear...
JUN 22, 2021 10:00 AM PDT
C.E. CREDITS
JUN 22, 2021 10:00 AM PDT
Date: June 22, 2021 Time: 10:00am (PDT), 1:00pm (EDT) Antimicrobial resistance (AMR) has emerged as one of the principal public health problems of the 21st century. It threatens the effectiv...
JUN 09, 2021 7:00 AM PDT
C.E. CREDITS
JUN 09, 2021 7:00 AM PDT
Date: June 9, 2021 Time: 09 June 2021, 7am PDT, 10am EDT, 4pm CEST cells with dramatic implications on the validity of past cell culture related research. The fact that at least 509 cell lin...
APR 12, 2017 9:00 AM PDT

Keynote Presentation - Assessing Risk in Cervical Cancer Screening Management: The Role of HPV Genotyping

Sponsored by: Roche Diagnostics

Specialty

Molecular Diagnostics

Laboratory Testing

Dna

Health

Biology

Genomics

Clinical Diagnostics

Therapy

Research

Behavior

Pcr/rt-Pcr/real-Time Pcr

Behavior Sciences

Molecular Genetics

Molecular Biology

Infectious Disease

Geography

North America67%

Asia17%

South America17%

Registration Source

Website Visitors100%

Job Title

Medical Laboratory Technician60%

Executive20%

Facility/Department Manager20%

Organization

Hospital17%

Pharmaceutical Company17%

Clinical Laboratory17%

Manufacturer - Other17%

Animal Hospital17%

Academic Institution17%


Show Resources
Loading Comments...
Show Resources